Global News

[ad_1] Moderna Covid-19 Vaccine mRNA 2024-2025 formula. Courtesy: Moderna A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. It's that time of the year again. A new round of Covid shots is on its way to Americans.  The Food and Drug Administration last week approved updated mRNA-based vaccines from Pfizer and Moderna amid a relatively large summer surge of the virus. Here's what you need to know, including how the shots are different this time around, who is eligible, where to get a vaccine and more.  What makes these shots different? U.S. health officials have long told patients to expect annual updates to Covid shots as the virus mutates into new strains that can dodge the immunity people develop from previous vaccinations or infections. It's similar to how the U.S. rolls out new flu shots each year.  This time, the shots fro...

[ad_1] Syringe with Covid-19 vaccine against the XBB Variant. Fight against virus Covid-19 Coronavirus, Vaccination and immunization. Undefined Undefined | Istock | Getty Images U.S. Food and Drug Administration staff on Monday said updated Covid boosters should target XBB omicron subvariants for the upcoming fall and winter vaccination campaign.  The U.S. should use a monovalent vaccine targeting either XBB.1.5, XBB.1.16, or XBB.2.3, collectively the dominant strains nationwide, the staff said in a briefing document .  related investing news The FDA staff made the conclusion ahead of a meeting on Thursday, when a panel of external advisors to the agency will recommend a strain for new Covid shots to target later this year. There is no set date for when the vaccination campaign will begin. Vaccine manufacturers will be expected to update their shots once that strain is selected. Pfizer , Moderna and Novavax are already developing versions of their respective vaccines targeti...

[ad_1] A nurse prepares doses of the Pfizer vaccine during a COVID-19 vaccination event at Josephine's Southern Cooking in Chatham, Illinois, Dec. 30, 2021. Brian Cassella | Tribune News Service | Getty Images A new round of Covid vaccines is finally here in the U.S. The Centers for Disease Control and Prevention cleared single-strain shots from Pfizer and Moderna for all Americans six months and up on Tuesday, following approvals from the Food and Drug Administration on Monday. Those mRNA vaccines are designed to target a relatively new omicron subvariant called XBB.1.5 .  The first doses of the new shots will be available at some pharmacies and other vaccine distribution locations within 48 hours of the CDC's recommendation, agency staff said Tuesday during a meeting of independent advisors to the CDC. That means jabs could reach Americans as soon as Thursday. Meanwhile, the FDA is still reviewing a third updated vaccine from Novavax for people ages 12 and up.  Th...

[ad_1] Nikos Pekiaridis | Nurphoto | Getty Images Stock Chart Icon Stock chart icon Novavax shares jump on news of a settlement payment from the Canadian government. It's unclear how many doses of Novavax's jab – its only commercially available product after 35 years – went unused. Under the amended agreement, Novavax will also provide Canada with fewer doses of its vaccine on a revised delivery schedule.  However, Canada can terminate the contract if Novavax fails to receive regulatory approval for vaccine production at the Canadian government's biomanufacturing facility by Dec. 31, 2024, according to the agreement. The announcement is another sign of hope for investors after the cash-strapped company raised doubts about its ability to stay in business earlier this year.  CNBC Health & Science Read CNBC's latest health coverage: In May, Novavax adopted a more positive outlook and announced a sweeping cost-cutting plan alongside its first-quarter earnings repor...